A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 24 Jan 2025
At a glance
- Drugs Atezolizumab (Primary) ; Migoprotafib (Primary) ; Omeprazole (Primary)
- Indications Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genentech
Most Recent Events
- 22 Jan 2025 Planned End Date changed from 31 May 2025 to 31 Mar 2026.
- 22 Jan 2025 Planned primary completion date changed from 31 May 2025 to 31 Mar 2026.
- 22 Jan 2025 Status changed from recruiting to active, no longer recruiting.